Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 46

Sort by

Sort Order Select

Journal Articles

Extent and Clinical Implications of Subclonal Diversity in Paroxysmal Nocturnal Hemoglobinuria

Mohammad Fahad B Asad, MD MBBS, Abhinav Goyal, MD, Hassan Awada, MD, Mai Aly, Cassandra Hirsch, Michael J. Clemente, Aziz Nazha, MD, Hetty E. Carraway, MD MBA, Sudipto Mukherjee, MD PhD MPH, Yasunobu Nagata, MD PhD, Jaroslaw P. Maciejewski, PhD MD FACP

Blood (2017) 130 (Supplement 1): 779.

https://doi.org/10.1182/blood.V130.Suppl_1.779.779

Published: 2017

Journal Articles

The Mechanisms By Which Mutant-NPM1 Uncouples Differentiation from Proliferation Are Reversed By Several Drugs, Enabling Rational Multi-Component Non-Cytotoxic Differentiation Therapy

Xiaorong Gu, PhD, Quteba Ebrahem, MD, Reda Z. Mahfouz, MD PhD, Metis Hasipek, PhD, Francis Enane, PhD, Tomas Radivoyevitch, Nicolas Rapin, PhDMSc, Bartlomiej P. Przychodzen, MSc, Ramesh Balusu, PhD, Claudiu V Cotta, David Wald, MD PhD, Zhenbo Hu, MD PhD, Yosef Landesman, PhD, Maria Paola Martelli, MD PhD, Brunangelo Falini, MD, Hetty E. Carraway, MD MBA, Jaroslaw P. Maciejewski, PhD MD FACP, Babal K Jha, PhD, Yogenthiran Saunthararajah, MD

Blood (2017) 130 (Supplement 1): 878.

https://doi.org/10.1182/blood.V130.Suppl_1.878.878

Published: 2017

Journal Articles

Distinct Clinical Phenotypes of Patients with Myeloid Neoplasms Carrying SF3B1 Hotspot Mutations

Blood (2017) 130 (Supplement 1): 2961.

https://doi.org/10.1182/blood.V130.Suppl_1.2961.2961

Published: 2017

Journal Articles

Atherosclerotic Arterial Disease-Related Mortality in Chronic Myeloid Patients Treated with Tyrosine Kinase Inhibitors

Remco J Molenaar, Tomas Radivoyevitch, Aziz Nazha, MD, Anjali S. Advani, MD, Aaron T. Gerds, MDMS, Jaroslaw P. Maciejewski, PhD MD FACP, Navneet S. Majhail, MD MS, Mikkael A. Sekeres, MD MS, Matt Kalaycio, MD, Sudipto Mukherjee, MD PhD MPH

Blood (2017) 130 (Supplement 1): 2871.

https://doi.org/10.1182/blood.V130.Suppl_1.2871.2871

Published: 2017

Journal Articles

No Excess Risk of Second Malignancies in Chronic Myeloid Leukemia (CML) Patients Treated with Tyrosine Kinase Inhibitors (TKIs)

Lilian Iglesias, Sudipto Mukherjee, MD PhD MPH, Aziz Nazha, MD, Anjali S. Advani, MD, Aaron T. Gerds, MDMS, Hetty E. Carraway, MD MBA, Matt Kalaycio, MD, Jaroslaw P. Maciejewski, PhD MD FACP, Navneet S. Majhail, MD MS, Mikkael A. Sekeres, MD MS

Blood (2017) 130 (Supplement 1): 2872.

https://doi.org/10.1182/blood.V130.Suppl_1.2872.2872

Published: 2017

Journal Articles

Prediction of Clinically Relevant Mutations in (MDS): A Report on Behalf of the MDS Clinical Research Consortium (CRC)

Sangmin Lee, MD, John Barnard, PhD, Rami S. Komrokji, MD, Amy E. DeZern, MD, David P. Steensma, MD, Jaroslaw P. Maciejewski, PhD MD FACP, Ellen K Ritchie, MD, Pinkal Desai, MDMPH, Felix Tavernier, MD, Duane C. Hassane, PhD, Guillermo Garcia-Manero, MD, Mikkael A. Sekeres, MD MS, Gail J. Roboz, MD

Blood (2017) 130 (Supplement 1): 2965.

https://doi.org/10.1182/blood.V130.Suppl_1.2965.2965

Published: 2017

Journal Articles

Model Heterogeneity in Predicting Outcomes of Patients with Myelodysplastic Syndromes (MDS)

Karam Al-Issa, MD, Yazan F. Madanat, MD, Sudipto Mukherjee, MD PhD MPH, Cassandra M. Hirsch, BS, Aaron T. Gerds, MDMS, Nour Abuhadra, MD, Ahed Makhoul, MD, Hassan Awada, MD, Mohammad Fahad B Asad, MD MBBS, Abhinav Goyal, MD, Anjali S. Advani, MD, Teodora Kuzmanovic, BA, Bartlomiej P. Przychodzen, MSc, Hetty E. Carraway, MD MBA, Jaroslaw P. Maciejewski, PhD MD FACP, Mikkael A. Sekeres, MD MS, Aziz Nazha, MD

Blood (2017) 130 (Supplement 1): 2972.

https://doi.org/10.1182/blood.V130.Suppl_1.2972.2972

Published: 2017

Journal Articles

Mutational Signatures Associated with Intensity and Duration of Smoking in Myelodysplastic Syndromes (MDS)

Yazan F. Madanat, MD, Tomas Radivoyevitch, PhD, Aziz Nazha, MD, Yazeed Sawalha, MD, Karam Al-Issa, MD, Nour Abuhadra, MD, Teodora Kuzmanovic, BA, Bartlomiej Przychodzen, Cassandra M. Hirsch, BS, Bhumika J. Patel, MD, David Seastone, PhDDO, Yogenthiran Saunthararajah, MD, Sudipto Mukherjee, MD PhD MPH, Anjali S. Advani, MD, Hetty E. Carraway, MD MBA, Aaron T. Gerds, MDMS, Jaroslaw P. Maciejewski, PhD MD FACP, Mikkael A. Sekeres, MD MS

Blood (2017) 130 (Supplement 1): 424.

https://doi.org/10.1182/blood.V130.Suppl_1.424.424

Published: 2017

Journal Articles

Distinct Genomic Associations to Predict Acute Myeloid Leukemia (AML) Progression from Myelodysplastic Syndromes (MDS)

Yazan F. Madanat, MD, Mikkael A. Sekeres, MD MS, Karam Al-Issa, MD, Cassandra M. Hirsch, BS, Sudipto Mukherjee, MD PhD MPH, Aaron T. Gerds, MDMS, Nour Abuhadra, MD, Babal K Jha, PhD, Vera Adema, PhD, Anjali S. Advani, MD, Yasunobu Nagata, MD PhD, Teodora Kuzmanovic, BA, Bartlomiej P. Przychodzen, MSc, Hetty E. Carraway, MD MBA, Jaroslaw P. Maciejewski, PhD MD FACP, Aziz Nazha, MD

Blood (2017) 130 (Supplement 1): 4245.

https://doi.org/10.1182/blood.V130.Suppl_1.4245.4245

Published: 2017

Journal Articles

Model Heterogeneity in Predicting Outcomes in Patients with Chronic Myelomonocytic Leukemia (CMML): An Overestimation of Survival in Lower-Risk Group

Aziz Nazha, MD, Mrinal M. Patnaik, MDMBBS, Rami S. Komrokji, MD, Karam Al-Issa, MD, Naval Daver, MD, Guillermo Garcia-Manero, MD, Jaroslaw P. Maciejewski, PhD MD FACP, Alan F. List, MD, Michael R. Savona, MD, Raphael Itzykson, MD PhD, Pierre Fenaux, MD PhD, Valeria Santini, MD, Ayalew Tefferi, MD, Mikkael A. Sekeres, MD MS, Eric Padron, MD

Blood (2017) 130 (Supplement 1): 4255.

https://doi.org/10.1182/blood.V130.Suppl_1.4255.4255

Published: 2017

Journal Articles

High Rates of Atherosclerotic Disease-Related Mortality in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia Patients Associated with TET2-Mutations

Remco J Molenaar, Tomas Radivoyevitch, PhD, Mikkael A. Sekeres, MD MS, Sudipto Mukherjee, MD PhD MPH, Jaroslaw P. Maciejewski, PhD MD FACP

Blood (2017) 130 (Supplement 1): 421.

https://doi.org/10.1182/blood.V130.Suppl_1.421.421

Published: 2017

Journal Articles

Clinical and Molecular Characteristics of Therapy-Related Acute Lymphoblastic Leukemia

Blood (2017) 130 (Supplement 1): 3993.

https://doi.org/10.1182/blood.V130.Suppl_1.3993.3993

Published: 2017

Journal Articles

How Somatic Mutations Carve Morphologic Imprint in MDS?

Abhinav Goyal, MD, Mohammad Fahad B Asad, MD MBBS, Hassan Awada, MD, Mai Aly, MD, Cassandra M. Hirsch, BS, Bartlomiej P. Przychodzen, MSc, Tomas Radivoyevitch, PhD, Aziz Nazha, MD, Sudipto Mukherjee, MD PhD MPH, Mikkael A. Sekeres, MD MS, Jaroslaw P. Maciejewski, PhD MD FACP, Yasunobu Nagata, MD PhD

Blood (2017) 130 (Supplement 1): 2949.

https://doi.org/10.1182/blood.V130.Suppl_1.2949.2949

Published: 2017

Journal Articles

A Personalized Prediction Model to Risk Stratify Patients with Myelodysplastic Syndromes (MDS)

Aziz Nazha, MD, Rami S. Komrokji, MD, John Barnard, PhD, Karam Al-Issa, MD, Eric Padron, MD, Yazan F. Madanat, MD, Teodora Kuzmanovic, BA, Nour Abuhadra, MD, David P. Steensma, MD, Amy E. DeZern, MD, Gail J. Roboz, MD, Guillermo Garcia-Manero, MD, Alan F. List, MD, Jaroslaw P. Maciejewski, PhD MD FACP, Mikkael A. Sekeres, MD MS

Blood (2017) 130 (Supplement 1): 160.

https://doi.org/10.1182/blood.V130.Suppl_1.160.160

Published: 2017

Journal Articles

Genomic Biomarkers to Predict Response to Hypomethylating Agents in Patients with Myelodysplastic Syndromes (MDS)

Aziz Nazha, MD, Mikkael A. Sekeres, MD MS, Rafael Bejar, MD PhD, Rami S. Komrokji, MD, John Barnard, PhD, Karam Al-Issa, MD, Bartlomiej P. Przychodzen, MSc, Cassandra M. Hirsch, BS, David P. Steensma, MD, Amy E. DeZern, MD, Gail J. Roboz, MD, Guillermo Garcia-Manero, MD, Benjamin L. Ebert, MD PhD, Jaroslaw P. Maciejewski, PhD MD FACP

Blood (2017) 130 (Supplement 1): 157.

https://doi.org/10.1182/blood.V130.Suppl_1.157.157

Published: 2017

Journal Articles

Targeting the MALAT1/PARP1/LIG3 Complex Induces DNA Damage and Apoptosis in Multiple Myeloma Mouse Models

Yi Hu, Jing Fang, Hua Fang, Chen Li, Shuang Liu, Sarah L. Ondrejka, MD, Zihua Gong, Jaroslaw P. Maciejewski, PhD MD FACP, Frederic J. Reu, MD, Qing Yi, MD PhD, Jianjun Zhao, MD

Blood (2017) 130 (Supplement 1): 1829.

https://doi.org/10.1182/blood.V130.Suppl_1.1829.1829

Published: 2017

Journal Articles

TET2 and MSH6: A Novel Role for MMR in the Pathogenesis of Myeloid Malignancies

Edward F Greenberg, MD, Cassandra M. Hirsch, BS, Feng Pan, PhD, Babal K Jha, PhD, Yihong Guan, PhD, Valeria Visconte, PhD, Dewen You, PhD, Guangbo Qu, PhD, Amy Graham, Bartlomiej P. Przychodzen, MSc, Thomas Laframboise, PhD, Hideki Makishima, MD PhD, Daniel Gackowski, PhD, Ryszard Ólinski, Professor, Yu-Wei Cheng, PhD, Mikkael A. Sekeres, MD MS, Mingjiang Xu, MDPhD, Jaroslaw P. Maciejewski, PhD MD FACP

Blood (2017) 130 (Supplement 1): 1668.

https://doi.org/10.1182/blood.V130.Suppl_1.1668.1668

Published: 2017

Journal Articles

A Phase 1 Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib (MLN9708) for Relapsed/ Refractory Acute Myeloid Leukemia (AML): Final Results

Blood (2017) 130 (Supplement 1): 150.

https://doi.org/10.1182/blood.V130.Suppl_1.150.150

Published: 2017

Journal Articles

Germline SAMD9 and SAMD9L Alterations in Adult Myelodysplastic Syndromes

Yasunobu Nagata, MD PhD, Bartlomiej P. Przychodzen, MSc, Cassandra M. Hirsch, BS, Hideki Makishima, MD PhD, Victor Pastor Loyola, MSc, Babal K Jha, PhD, Teodora Kuzmanovic, BA, Tomas Radivoyevitch, PhD, Vera Adema, PhD, Kenichi Yoshida, MD PhD, Samuel Li, BA, Francesc Sole, PhD, Thomas Laframboise, PhD, Rabi Hanna, MD, Mikkael A. Sekeres, MD MS, Seishi Ogawa, MD PhD, Marcin W. Wlodarski, MD PhD, Jorg Cammenga, MD, Jaroslaw P. Maciejewski, PhD MD FACP

Blood (2017) 130 (Supplement 1): 1670.

https://doi.org/10.1182/blood.V130.Suppl_1.1670.1670

Published: 2017

Journal Articles

Chemotherapy and Radiation Results in Distinct Patterns of Somatic Mutations in Subsequent Myeloid Disease

Teodora Kuzmanovic, BA, Tomas Radivoyevitch, PhD, Srinivasa Reddy Sanikommu, MD, Bhumika J. Patel, MD, Yasunobu Nagata, MD PhD, Cassandra M. Hirsch, BS, Bartlomiej P. Przychodzen, MSc, Sudipto Mukherjee, MD PhD MPH, Anjali S. Advani, MD, Aziz Nazha, MD, Aaron T. Gerds, MDMS, Hetty E. Carraway, MD MBA, Mikkael A. Sekeres, MD MS, Jaroslaw P. Maciejewski, PhD MD FACP

Blood (2017) 130 (Supplement 1): 1673.

https://doi.org/10.1182/blood.V130.Suppl_1.1673.1673

Published: 2017

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Extent and Clinical Implications of Subclonal Diversity in Paroxysmal Nocturnal Hemoglobinuria

The Mechanisms By Which Mutant-NPM1 Uncouples Differentiation from Proliferation Are Reversed By Several Drugs, Enabling Rational Multi-Component Non-Cytotoxic Differentiation Therapy

Distinct Clinical Phenotypes of Patients with Myeloid Neoplasms Carrying SF3B1 Hotspot Mutations

Atherosclerotic Arterial Disease-Related Mortality in Chronic Myeloid Patients Treated with Tyrosine Kinase Inhibitors

No Excess Risk of Second Malignancies in Chronic Myeloid Leukemia (CML) Patients Treated with Tyrosine Kinase Inhibitors (TKIs)

Prediction of Clinically Relevant Mutations in (MDS): A Report on Behalf of the MDS Clinical Research Consortium (CRC)

Model Heterogeneity in Predicting Outcomes of Patients with Myelodysplastic Syndromes (MDS)

Mutational Signatures Associated with Intensity and Duration of Smoking in Myelodysplastic Syndromes (MDS)

Distinct Genomic Associations to Predict Acute Myeloid Leukemia (AML) Progression from Myelodysplastic Syndromes (MDS)

Model Heterogeneity in Predicting Outcomes in Patients with Chronic Myelomonocytic Leukemia (CMML): An Overestimation of Survival in Lower-Risk Group

High Rates of Atherosclerotic Disease-Related Mortality in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia Patients Associated with TET2-Mutations

Clinical and Molecular Characteristics of Therapy-Related Acute Lymphoblastic Leukemia

How Somatic Mutations Carve Morphologic Imprint in MDS?

A Personalized Prediction Model to Risk Stratify Patients with Myelodysplastic Syndromes (MDS)

Genomic Biomarkers to Predict Response to Hypomethylating Agents in Patients with Myelodysplastic Syndromes (MDS)

Targeting the MALAT1/PARP1/LIG3 Complex Induces DNA Damage and Apoptosis in Multiple Myeloma Mouse Models

TET2 and MSH6: A Novel Role for MMR in the Pathogenesis of Myeloid Malignancies

A Phase 1 Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib (MLN9708) for Relapsed/ Refractory Acute Myeloid Leukemia (AML): Final Results

Germline SAMD9 and SAMD9L Alterations in Adult Myelodysplastic Syndromes

Chemotherapy and Radiation Results in Distinct Patterns of Somatic Mutations in Subsequent Myeloid Disease

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only